Comparative Pharmacology

Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

Electrolyte

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Potassium chloride provides potassium ions essential for maintenance of cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose 5% supplies calories and may reduce protein and nitrogen losses. Sodium chloride 0.3% supplies sodium and chloride ions to maintain electrolyte balance.

Clinical Dosing

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Intravenous infusion: 10-20 mEq/hour, not exceeding 30 mEq/hour or 200 mEq/24 hours; rate depends on severity of hypokalemia and patient tolerance.

Direct Interaction

None Documented